Chokri Ben Lamine/LinkedIn
Jun 12, 2026, 16:14
Chokri Ben Lamine: EHA26 – SCD Curative Therapy Pathway
Chokri Ben Lamine, Assistant Consultant at King Faisal Specialist Hospital and Research Center, shared a post on X:
“EHA26 – SCD Curative Therapy Pathway
EHA-SWG and EBMT-HWP joint recommendations highlight who should be considered for:
- Allogeneic HCT
- Cell and gene therapy
in sickle cell disease
Key clinical logic:
- Confirm HbSS and severe HbSβ⁰ genotype
- Assess for severe clinical presentation
- If HLA-matched family donor is available, proceed to allo-HCT assessment
- If no matched donor is available and eligibility criteria are met, assess for gene therapy at a transplant center.
Practical message:
Curative therapy in SCD is becoming algorithm-driven, but still needs expert individualized review:
- genotype
- disease severity
- donor availability
- age
- regulatory and scientific updates
- patient-centered risk–benefit discussion
Session: Optimising the transplant process in haemoglobinopathies
Chair: Ben Carpenter”
Other posts featuring Chokri Ben Lamine on Hemostasis Today.
-
Jul 28, 2026, 07:10Wolfgang Miesbach: How Safe Is AAV Gene Therapy?
-
Jul 28, 2026, 06:59Fiona Robinson: New MASAC Recommendations for Iron Deficiency – Live Webinar
-
Jul 28, 2026, 06:49Vera Ghali: What Else Do Platelets Do Besides Clotting?
-
Jul 28, 2026, 02:54Joseph R. Shaw: Why Stroke Occurs Despite Anticoagulation
-
Jul 28, 2026, 02:45Are VWD Clinical Trials Missing What Matters Most to Women? – RPTH
-
Jul 28, 2026, 02:38Umberto Pensato: New BMJ Review on Breakthrough Stroke in Patients Receiving DOACs Is Now Live
-
Jul 27, 2026, 17:29Muhammad Numan: Normal MCV Does Not Exclude B12 Deficiency
-
Jul 27, 2026, 17:15ISTH 2026 Congress Paris Opens with a Powerful Message: Science Beyond Border
-
Jul 27, 2026, 17:14Michael Ombrello։ Decoding How Autoantibodies Cause Disease